Cullinan Therapeutics has filed an investigational new drug application with the U.S. Food and Drug Administration (FDA) for CLN-978 for the treatment of systemic lupus erythematosus (SLE).

In a new study, researchers investigated the prevalence of cardiovascular disease events (CVE) in people with systemic lupus ...

Nos unimos con Melanie Betz de la American Kidney Fund para responder algunas de las preguntas más frecuentes sobre la dieta y la nutrición al enfrentar complicaciones renales y lupus. La siguiente ...

The following transcript is automatically generated and may contain typos or misspellings. Please listen to the episode for the most accurate language. Host 0:03 Welcome everyone to the first week of ...

In a recent study, researchers explored the association between HCQ and the overall risk of CV events in people with SLE.

CAR cell therapy is a category of potential new treatments for lupus and other autoimmune diseases. CAR cell therapies use a protein called a chimeric antigen receptor (CAR) to modify immune cells and ...

The PALIZADE clinical study is evaluating zetomipzomib for the treatment of lupus nephritis, its side effects, and how it affects proteins in the urine. The PALIZADE clinical trial is made up of 3 ...

People with lupus have two categories of risk factors for heart disease. The traditional risk factors that affect the general population apply to people with lupus and appear more frequently among ...